LifeCycle Pharma enlists Morgan Stanley to prepare for IPO listing  

2005.07.26
Danish biotech company LifeCycle Pharma has enlisted investment bank Morgan Stanley to help prepare for an IPO on Copenhagen Stock Exchange probably by the end of this year

Danish biotech company LifeCycle Pharma has enlisted investment bank Morgan Stanley to help prepare for an IPO on Copenhagen Stock Exchange probably by the end of this year. Morgan Stanley has successfully assisted in IPOs of biotech companies such as Scotland's Prostrakans and US based Adam Respiratory Therapeutics this year.

Michael Wolff Jensen, finance director at LifeCycle Pharma says the company aims to link an IPO together with the company's first filing for drug registration and a partnership agreement which are expected to happen before the end of 2005: "We know the preparations for an IPO take time and we have thus hired Morgan Stanley to help us with the preparations and to decide the timing".

LifeCycle Pharma is based in Hørsholm north of Copenhagen. The company has developed a clinically validated drug-delivery platform that solves the insufficiencies of drugs with low water solubility, thereby improving the bioavailability of marketed drugs and new chemical entities (NCEs). The company is owned by Lundbeck, Novo A/S, Nordic Biotech, Alta Partners and Adamant Biomedical. The news is reported by financial daily newspaper Børsen.

Link > LifeCycle Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×